Bosentan effect on Teneligliptin’s Antidiabetic effect in Animal Model

Abstract

Due to a variety of comorbidities, Patients with type 2 diabetes usually require a multifaceted approach to therapy. A large number of medications taken at the same time increase the risk of undesirable drug effects or drug interactions in the patient. It's vital to think about cytochrome P-450 (CYP) enzyme interactions while using a multifactorial pharmacotherapy approach. The cytochrome P450 enzymes CYP2C9 and CYP3A4 metabolize bosentan in the liver similarly, teneligliptin is metabolized by flavin-containing monooxygenase 3 (FMO3) and cytochrome P450 (CYP) 3A4. This study was conducted to investigate a possible pharmacokinetic interaction between bosentan and teneligliptin. Interaction of teneligliptin, the known dipeptidyl peptidase-4 inhibitors or gliptins anti diabetic drugs with bosentan, a pulmonary antihypertensive agent, in healthy and alloxan-induced diabetic rats, was tested. Blood samples were taken from rats at various intervals up to 24 hours and blood glucose levels were calculated. The parameters considered for the analysis of the effect on teneligliptin induced hypoglycemia were the onset of hypoglycemia (duration required to reduce blood glucose level by 15% - 20%), duration of hypoglycemia (duration of time in which more than 15 % -20 % decrease in blood glucose level is managed to maintained), and peak hypoglycemia. In both healthy albino rats and diabetic rats, a single dose of bosentan did not affect blood glucose levels. These results suggest that bosentan has no hypoglycemic effect, implying that the drug-drug interaction with teneligliptin is of the pharmacokinetic kind.